share_log

Xilio Therapeutics shares are trading lower after the company provided an update of its preliminary Phase 1 dose-escalation data for XTX101. The company also reported Q2 financial results.

Benzinga ·  Aug 9, 2022 22:10
Xilio Therapeutics shares are trading lower after the company provided an update of its preliminary Phase 1 dose-escalation data for XTX101. The company also reported Q2 financial results.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment